
### HIFU: Ready for Prime Time!

David C. Beyer MD FACR, FACRO, FASTRO
Cancer Centers of Northern Arizona
Heathcare
Sedona, Arizona



Nothing else in the world . . . not all the armies . . . is so powerful as an idea whose time has come.

-Victor Hugo

#### HIFU

- \* Used for at least 2 decades outside US
- \* Approved in 50 countries
- Minimally invasive
- \* Ultrasound or MRI guided
- \* Transrectal or transurethral systems
- \* Outpatient
- \* Rapid recovery
- Minimal GU/sexual toxicity
- \* No bleeding
- \* No radiation to OAR's

## Damage to sensitive organs often considered unacceptable after radiation or prostatectomy



## Phase II/III Prospective Multicenter HIFU

#### \* 402 patients with mean

- \* Age 69.3 years
- \* Volume 28cc
- \* PSA 10.9
- \* Follow up 407 days
- \* Negative re-biopsy 87.2%
  - \* 92.1% in low risk

#### **MRI Guided HIFU**

- \* Transperineal mapping biopsy
  - \* 1-2 lesions, <10mm
- \* mpMRI
- \* Toxicity at 2 year follow up
- \* Slight insignificant deterioration EPIC urinary score
- \* Trend decrease sexual function (4.4 points)
- \* No significant change in EPIC subdomain score

## Salvage HIFU After Failed EBRT

- Whole gland HIFU
- \* 81% 1 year negative biopsy
- \* AE in 91/100 patients
  - \* 67 Grade I
  - \* 80 Grade II
  - \* 20 Grade III


## Longer follow up

- \* 569 men with median age 65 yrs
- \* Risk grouping: Low 28%, intermediate 56%, High 14%
- \* Repeat HIFU in 163
- \* Median F/U 46 months
- \* 5 yr Failure Free 70%
  - \* Low 87%
  - \* Intermediate 63%
  - \* High 58%
- \* 7.7% UTI
- \* 88% pad free

#### Whole Gland Ablation

- \* 1002 patients
- \* Primary prostate cancer
- \* 60% 1 session 38% 2 sessions
- \* 8 year biochemical free survival (Phoenix)
  - \* 76% low 63% Intermed 57% high risk
- \* 10 year PCa specific survival 97%
  - \* Metastasis-free survival 94%


#### **bDFS** with HIFU



#### More late results HIFU

- \* 702 patients retrospective
  - \* T1-2, PSA<50, no ADT
  - \* 78.5% intermediate or high risk
  - \* Mean F/U 5.3 years
- \* Ablatherm® HIFU
- \* Cancer specific survival 99%
- \* 10 year freedom from salvage Tx 98% (low), 72% (intermed), 68% (high)
- \* 10 year Metastasis free survival 95%


#### **ProtecT Trial**



## Large Studies with Long Follow-up

- \* 538 consecutive retrospective patients
- \* Median F/U 8.3 years
- \* Ablatherm™
- \* Risk groups: Low 42.6%, Intermed 39.2% High 16.9%

# Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer



#### **Multi-Center Trial**

- \* Multicenter French study
  - \* T1c-T2, PSA<15, ≤2 sextants involved
  - \* mpMRI urethra ≥ 5mm from tumor
- \* Focal HIFU
- \* 96 / 101 patients without evidence of clinically significant PCa on F/U biopsy
  - \* 87% no cancer in treated lobe
  - \* 67% no cancer in entire gland
- \* 97.2% without pads (stress incontinence 2.8%)
- \* 78.4% preserved erectile function

### **HIFU Meta-Analysis**

- \* 13 studies
  - \* 11 primary
  - \* 2 salvage
- \* 543 patients
- \* Median F/U 0.5-10.6 years
- \* 14% required subsequent oncologic therapy

## **Clinical Trials Ongoing**

- ExAblate MR Guided Focused Ultrasound
  - \* NCT01657942
- Endocare CRYOcare vs Galil Medical CRYO-HIT
  - \* NCT00295802

### Case Selection is Key

- Treat whole gland when needed
- \* Treat focally when not
- \* May be bridge between active surveillance and more aggressive surgery

## Approved By FDA for "prostate ablation"


- Different technologies and protocols
- \* Lack of consensus on ideal candidate

#### HIFU

## Are we just where brachytherapy was 20 years ago?



#### Trends in Prostate Cancer



Mettlin, Murphy, McDonald, and Menck 1999;86:1877-82

Cancer




## ABS Consensus Dose HDR

Center	XRT	HDR
CET	36Gy	6Gy x4
LBMMC	39.6 Gy	5.5-6.5 Gy x4
MMC	45 Gy	5.5 Gy x4
SPI	45-50.4 Gy	4 Gy x4
		6 Gy x3
WBH	46 Gy	9.5 Gy x2
Kiel	50.4	15 Gy x2

Rodriguez et al, Brachy 17:265-282, 2001

### LDR Brachytherapy Monotherapy





\*Int = Intermediate; † yr = Year; †† CI = Confidence interval







Latest Headlines | Health | Health Directory | Coupons



OUR LOWEST RATES ONLY AT MARRIOTT.COM Book a hotel near Flagstaff, AZ From \$119 SpringHill Suites Flagstaff

#### Keep your pecker up, Bill...new prostate cancer zapper won't wreck your love life! Pioneering soundwave treatment proves as effective as surgery

- · High-intensity focused ultrasound blasts tumours with soundwaves
- · Study shows its 93 per cent success rate as effective as surgery
- · But rate of erectile dysfunction in HIFU patients post treatment much lower
- 'Experimental' treatment not widely available in UK and costs £10,000

By BARNEY CALMAN, HEALTH EDITOR FOR THE MAIL ON SUNDAY PUBLISHED: 17:00 EDT. 12 March 2016 | UPDATED: 20:00 EDT. 12 March 2016



side effects.

incontinence.



blast away prostate tumours has been

gland - while causing significantly fewer

high-intensity focused ultrasound (HIFU), has been considered experimental.

proven to cure as many men of the disease as surgery that removes the

Until now the new procedure, called

This has meant that the majority of British men diagnosed with the condition - who include former Rolling Stone Bill Wyman - are offered the more

invasive operation called radical

prostatectomy, which has a clear track record despite the risk of impotence and

But a landmark study to be announced













DON'T MISS

Fregnant Khloe Kardashian locks lip

with boyfriend Trist

as she gives

## When Does a New Treatment Become A Standard of Care

- \* No perfect answer
- \* "Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology"
  - \* National Academies of Medicine Workshop, July 2015
- \* The bar is higher now than ever before
- \* Hypothesis generating studies
- \* Multicenter studies
- \* Meta Analyses
- \* Widely available



